Low-dose radiation plus immunotherapy for stomach and colon cancer spread in the belly
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of low-dose radiation therapy, immunotherapy, and chemotherapy for people whose stomach or colon cancer has spread to the lining of the belly (peritoneal cavity). The goal is to see if this approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or colon cancer that has spread to the belly lining (confirmed by biopsy).
- You are in generally good health (able to do daily activities, like walking and light chores).
- You have at least 3 months of expected survival.
- Your heart, liver, kidneys, and blood counts are working well enough.
- You are willing to sign a consent form and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, immunotherapy, chemotherapy, and intraperitoneal perfusion for gastric cancer that has spread to the abdominal lining and is not removable by surgery. It aims to see if this treatment can help control the cancer after first-line chemotherapy has stopped working.
This trial tests a combination of precise radiation to liver or lung tumors plus immunotherapy for people with advanced colorectal cancer that cannot be surgically removed. It aims to see if this approach can help control the cancer.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a new combination of treatments for stomach cancer that has spread to the lining of the abdomen. It uses an immunotherapy drug (tislelizumab) with chemotherapy (SOX) and heated chemotherapy directly into the abdomen (HIPEC) to see if it works better than standard care.
Hear when a new LDRT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.